A publications lead at a mid-size sponsor is looking at a 2027 publication plan that has to thread a needle: a pivotal Phase 3 trial reads out in eight months, the primary manuscript has to land in a high-impact journal within the embargo window, a congress presentation at the major therapeutic-area meeting has to come first without compromising the manuscript, a plain-language summary is now legally expected alongside the trial result under the EU Clinical Trial Regulation, and every author on every output has to satisfy the four ICMJE authorship criteria or be correctly listed as a non-author contributor. The plan touches a dozen outputs, six authors with different contribution profiles, two agencies, and a Good Publication Practice 2022 governance overlay that an auditor or a journal editor can ask about at any point. The temptation is to use a large language model as a fast ghostwriter that produces the manuscript and the summary. That framing fails GPP 2022 in the first sentence, because GPP 2022 is not about who typed the words; it is about whether the output is transparent, accountable, and authored by people who meet defined criteria. This lesson designs the end-to-end workflow that runs the publication-plan-to-manuscript-to-plain-language-summary lifecycle with GPP 2022 alignment built into the structure rather than bolted on at the end.

Why GPP 2022 Reframes What the Model Is Allowed to Do

Good Publication Practice 2022, the third update to the GPP guidelines, governs the ethical and transparent reporting of company-sponsored research, and its central concerns are authorship integrity, transparency of the sponsor's role, disclosure of writing support, and the prevention of selective or redundant reporting. The instant you introduce a large language model into this lifecycle, you collide with every one of those concerns, because the model can draft text that no human contributor has actually reasoned through, can blur the line between professional medical-writing support and authorship, and can produce fluent claims that drift from the locked statistical analysis. GPP 2022 does not prohibit AI assistance, but it does demand that the human accountability structure remain intact and visible, which means the workflow has to be designed so that the model accelerates production without ever becoming an author or a hidden hand.

This reframing changes the design goal. The model is not a ghostwriter; it is an accelerant operating inside a governance frame where named authors take public responsibility for the content, the sponsor's role is disclosed, professional writing support is acknowledged, and the use of AI is handled according to the destination journal's and the ICMJE's evolving expectations on disclosing AI assistance. A workflow that produces a beautiful manuscript but cannot show who authored which scientific judgment, who is accountable for the data interpretation, and how AI was used has produced a document that a journal can reject and an auditor can flag. The discipline of this lesson is to make the authorship and transparency structure a first-class part of the pipeline, tracked from the publication plan all the way to the published output and its plain-language companion.

Stage One: The Publication Plan as the Governing Artifact

The workflow begins not with a manuscript but with the publication plan, the governing artifact that GPP 2022 expects to exist and that defines, for each planned output, the target audience, the journal or congress, the data on which it draws, the author group, and the timeline. The model is genuinely useful here as a planning assistant: given the trial's analysis populations, the endpoints, and the strategic objectives, it can propose a coherent map of outputs, primary manuscript, secondary analyses, congress abstracts and presentations, the plain-language summary, that avoids the redundant-publication trap by making each output's distinct contribution explicit. This is real value, because a poorly planned publication program is how sponsors end up with salami-sliced papers that journals and ethics bodies treat as a transparency failure.

The plan is also where the authorship architecture is set, and this is the most consequential human decision in the lifecycle. The four ICMJE criteria, substantial contribution to conception or analysis, drafting or critical revision for intellectual content, final approval of the version to be published, and accountability for the work, must each be satisfied by every named author, and the plan records who is expected to meet them for each output. A model can draft a candidate author list from contribution records, but it cannot confer authorship, because authorship is an ethical determination about intellectual contribution and accountability that only the contributors and the publication steering function can make. The workflow captures the author-criteria mapping at the plan stage and carries it forward, so that by the time the manuscript exists, the question of who is an author and why has a documented answer rather than a last-minute negotiation.

Stage Two: The Congress-to-Manuscript Pipeline

A pivotal trial typically debuts at a congress before the full manuscript publishes, and the congress-to-manuscript pipeline is where timing, embargo, and consistency all have to be managed at once. The congress abstract and presentation present a constrained, early view of the data; the manuscript presents the complete analysis; and the two must be scientifically consistent without the congress output disclosing so much that it triggers a journal's prior-publication concern. The model accelerates this pipeline by drafting the abstract from the locked results, generating presentation content and speaker notes, and then carrying the consistent factual spine forward into the manuscript draft, which reduces the classic failure where the congress numbers and the manuscript numbers diverge because two different people drafted them from two different data cuts.

The verification burden here is specific and easy to underestimate. Because the model is generating the abstract, the presentation, and the manuscript from the same underlying results, an error introduced early propagates into every downstream output with the model's characteristic consistency, so a misstated confidence interval in the abstract can reappear, identical and wrong, in the manuscript. The named authors and the medical writer must reconcile every quantitative claim across all three outputs against the single locked source, the statistical analysis output, and confirm that the congress disclosure stays within the bounds the target journal accepts as not constituting prior publication. The pipeline's value is consistency; its risk is that consistency is agnostic to truth, so a consistently propagated error is as fluent as a consistently propagated fact, and only reconciliation to the locked analysis tells them apart.

Stage Three: Manuscript Drafting Inside the Authorship Frame

The manuscript draft is where the model does its highest-volume work and where the authorship frame is most easily violated. The model can produce a structured draft following the journal's and the relevant reporting guideline's expectations, CONSORT for the randomized trial, with the introduction, methods, results, and discussion populated from the protocol, the statistical analysis plan, and the locked results. This is a substantial acceleration of the blank-page phase, and it is legitimate as long as the named authors then do the work that authorship actually requires: engaging with the data interpretation, exercising critical intellectual judgment, revising the scientific argument, and taking public accountability for the conclusions.

The line that must not be crossed is the line between professional medical-writing support and authorship, and AI assistance pushes on it from a new direction. Professional medical writers who draft under author direction are acknowledged, not listed as authors, when they do not meet the ICMJE criteria, and this is long-settled practice. A large language model is not a person and cannot be an author or an acknowledged contributor in the human sense; what the workflow must instead capture is that AI was used as a tool, how it was used, and that the named human authors remain fully accountable for every claim, in line with how the destination journal and the ICMJE expect AI assistance to be disclosed. The failure mode is a manuscript where the intellectual content was effectively generated by the model and lightly approved by humans who did not genuinely exercise the judgment authorship requires; that manuscript has named authors who do not actually meet the criteria, which is exactly the integrity failure GPP 2022 exists to prevent.

Stage Four: Plain-Language Summary Production

The plain-language summary is now a structural output of the lifecycle rather than an afterthought, because the EU Clinical Trial Regulation requires a summary of results understandable to a layperson for trials in its scope, and journals and patient-engagement expectations increasingly call for a plain-language companion to the primary manuscript. The model is well suited to the core transformation, converting a dense, technical manuscript into accurate prose at a lay reading level, because reading-level adaptation and plain-language rephrasing are tasks it does fluently. Done well, this stage produces in hours a draft that historically took specialist effort and often slipped past the deadline.

The risk in plain-language production is subtle and clinically serious: the transformation from technical to lay language is exactly where meaning gets distorted, because simplifying a hedged, carefully bounded scientific finding into accessible prose tempts the model to overstate certainty, drop the qualifications that make the claim true, or imply a benefit the trial did not establish. A plain-language summary that tells a patient the drug works, when the manuscript says it improved a surrogate endpoint in a specific population with defined limitations, is not a simplification; it is a misstatement with patient-facing consequences. The workflow therefore treats the plain-language summary as a regulated scientific output in its own right: every simplified claim is reconciled against the corresponding manuscript statement to confirm that accessibility did not cost accuracy, the balance of benefit and limitation is preserved, and a named author who is accountable for the manuscript is also accountable for its lay companion. Plain language is a faithfulness problem, not a vocabulary problem.

Stage Five: Authorship and ICMJE Tracking Across the Lifecycle

Threaded through every stage is the authorship and ICMJE tracking layer, the part of the workflow that turns GPP 2022 from a principle into a record. For each output, the workflow tracks which named authors are proposed, which of the four ICMJE criteria each has met and through what contribution, who provided professional writing support and is therefore acknowledged rather than authored, how the sponsor's role is disclosed, and how AI assistance was used and disclosed per the destination's requirements. The model can help maintain this tracking by drafting contribution statements and disclosure language from the underlying records, but the determinations, who qualifies as an author, what the sponsor's role disclosure says, whether a contributor crossed into authorship, are governance decisions owned by the publication steering committee and the authors themselves.

The audit trail that results is what lets the workflow answer the questions that come from journals, ethics bodies, and internal compliance. For each output, the record holds the publication plan entry, the author-criteria mapping, the writing-support acknowledgment, the sponsor-role disclosure, the AI-use disclosure, the reconciliation of quantitative claims to the locked analysis, and the named approvals. When a journal editor asks whether every listed author meets the ICMJE criteria, or when an internal audit asks how AI was used in producing a manuscript, the answer is in the record rather than in someone's memory. The model accelerated drafting across the manuscript, the congress assets, and the plain-language summary; the named authors own the science, the publication steering function owns authorship and transparency, and GPP 2022 compliance is a property of the workflow's structure rather than a claim made about it after the fact.

Validating the Publication Workflow as a System

As a Level 3 design, the publication lifecycle is validated rather than merely run, and the validation lens clarifies where AI assistance is appropriate and where it is not. The intended-use statement pins the workflow's purpose: accelerating the production of GPP-2022-compliant publication outputs from locked trial data, explicitly not generating scientific conclusions or conferring authorship. The fitness-for-purpose assessment then grades each stage by the consequence of an undetected error. Plan-stage author mapping is governance-critical because a mistake corrupts the integrity of every downstream output; quantitative drafting is high risk because a propagated numerical error reaches a peer-reviewed claim; plain-language transformation is high risk because a distorted claim is patient-facing; and reading-level adaptation of already-verified prose is comparatively low risk.

The performance qualification of this workflow is concrete and inspectable. It means running the pipeline on a representative dataset with a known, locked analysis and confirming that every quantitative claim in the abstract, presentation, manuscript, and plain-language summary reconciles to the source, that no claim drifted in simplification, and that the authorship and disclosure records were generated completely and correctly. A pipeline that produces a fluent manuscript but lets one confidence interval drift between the abstract and the results section is not qualified, and the only way to know is to test reconciliation against a seeded dataset that includes the hard cases: a subgroup result, a non-significant secondary endpoint, and a hedged benefit statement that must survive plain-language transformation intact. The qualification record, kept under change control, is what lets the publications function assert that the workflow produces compliant outputs by design, which is the difference between a faster process and a defensible one.

Where the Lifecycle Fails Under Pressure

Each stage has a pressure point where a deadline tempts a shortcut that breaks GPP 2022 alignment. Skip the publication-plan author-criteria mapping and decide authorship at submission, and you invite the gift-authorship and ghost-authorship failures the guideline exists to prevent, because authorship negotiated under deadline pressure tends to reward seniority over contribution. Let the model effectively author the intellectual content while humans rubber-stamp it, and you have named authors who do not meet the ICMJE criteria, which is an integrity failure a journal can treat as misconduct. Let the plain-language summary overstate the result to make it more readable, and you have published a patient-facing misstatement that no amount of manuscript accuracy redeems.

The deepest failure is treating the whole lifecycle as a content-production problem rather than a governance problem. A team that optimizes purely for speed and polish will produce outputs that read beautifully and cannot survive scrutiny of how they were authored, disclosed, and reconciled. The correct design keeps the governance artifacts, the plan, the author-criteria mapping, the disclosures, the reconciliation record, in lockstep with the content artifacts, so that producing the manuscript and producing its accountability record are the same act rather than sequential ones. GPP 2022 alignment is not a review you pass at the end; in a well-designed AI-integrated workflow it is the structure the content is produced inside, which is why the model can safely accelerate the lifecycle without ever becoming the author of record.

Key Takeaways

• GPP 2022 reframes the model from ghostwriter to accelerant inside a governance frame. The guideline cares about authorship integrity, transparency of the sponsor's role, disclosure of writing support, and prevention of redundant reporting, so the workflow must keep the human accountability structure intact and visible; the model can draft, but it can never be an author or a hidden hand.
• The publication plan is the governing artifact, and the author-criteria mapping is its most consequential decision. Every named author must satisfy all four ICMJE criteria, and the workflow captures who is expected to meet them for each output at the plan stage, so that authorship has a documented answer rather than a last-minute negotiation that rewards seniority over contribution.
• The congress-to-manuscript pipeline buys consistency but consistency is agnostic to truth. Drafting the abstract, presentation, and manuscript from one locked analysis prevents divergent numbers, but an error introduced early propagates identically into every output, so the named authors reconcile every quantitative claim against the single locked statistical source and keep congress disclosure within the journal's prior-publication bounds.
• Plain-language production is a faithfulness problem, not a vocabulary problem. Simplifying a hedged scientific finding tempts the model to overstate certainty or imply an unestablished benefit, so the plain-language summary is treated as a regulated output where every simplified claim is reconciled against its manuscript statement and a named author accountable for the manuscript is accountable for its lay companion.
• GPP 2022 alignment is a property of the workflow's structure, not a review passed at the end. Authorship and ICMJE tracking thread through every stage, keeping the plan, author-criteria mapping, sponsor-role disclosure, AI-use disclosure, and reconciliation record in lockstep with the content, so that when a journal editor or auditor asks how a manuscript was authored and disclosed, the answer is in the record rather than in memory.